By Adria Calatayud
e-Therapeutics PLC said Friday that it expects to receive payments from Galapagos NV after meeting two milestones under a collaboration agreement between the two companies.
U.K.-based e-Therapeutics, a provider of technology services for drug discovery, said the collaboration--which seeks to identify new therapeutic approaches for the treatment of idiopathic pulmonary fibrosis and other fibrotic conditions--has remained on schedule despite the coronavirus pandemic.
Under the terms of its agreement with Galapagos, e-therapeutics is eligible to receive additional milestone payments, it said.
Write to Adria Calatayud at adria.calatayud@dowjones.com
(END) Dow Jones Newswires
04-23-21 0308ET